UBS has reduced its price target for DocMorris from 27 to 25 francs, maintaining a "Sell" rating. Analyst Sebastian Vogel noted that the online pharmacy's recent statements indicate a slowdown in growth for prescription drugs in the German market in the near term.
UBS has reduced its price target for DocMorris from 27 to 25 francs, maintaining a "Sell" rating. Analyst Sebastian Vogel noted that the online pharmacy's recent statements indicate a weaker growth outlook for prescription drugs in the German market in the near term.
UBS has downgraded its price target for DocMorris from 27 to 25 francs, maintaining a "Sell" rating. Analyst Sebastian Vogel noted that the online pharmacy's recent statements indicate a weaker growth outlook for prescription drugs in the German market in the near term.
UBS has maintained a 'Sell' rating for DocMorris, setting a price target of 27 francs following the third quarter results. Analyst Sebastian Vogel noted that the online pharmacy's sales met expectations, but anticipates a slight negative reaction in share prices as DocMorris continues to lag behind its main German competitor in the prescription market.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
